On or around 05/16/2017 (Stipulation and order of dismissal (voluntary dismissal))
Filing Date: May 02, 2017
According to the Complaint, On January 21, 2017, the Board caused the Company to enter into an agreement and plan of purchase ("Purchase Agreement"), pursuant to which the Company will acquire certain assets and assume certain liabilities constituting the therapy business of Biotest (the "Proposed Transaction") in exchange for an aggregate equity interest in ADMA equal to approximately 50% of the issued and outstanding ADMA capital stock (the "Purchase Consideration").
The Complaint alleges on April 26, 2017, in order to convince ADMA shareholders to vote in favor of the Proposed Transaction, the Board authorized the filing of a materially incomplete and misleading Definitive Proxy Statement (the "Proxy") with the Securities and Exchange Commission ("SEC"), in violation of Sections 14(a) and 20(a) of the Exchange Act.
On May 10, 2017, Plaintiff filed a Notice voluntarily dismissing this action. The Court granted an Order of Dismissal on May 16.
Company & Securities Information
Defendant: ADMA Biologics, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: ADMA
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Jonathan English, et al. v. ADMA Biologics, Inc., et al.
COURT: D. New Jersey
DOCKET #: 17-CV-03128
JUDGE: Hon. Susan D. Wigenton
DATE FILED: 05/02/2017
CLASS PERIOD START: 01/21/2017
CLASS PERIOD END: 05/02/2017
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Monteverde & Associates PC 350 Fifth Avenue, 59th Floor, Monteverde & Associates PC, NY 10118 (212) 971-1341 ·
First Identified Complaint (FIC) Filings:
Class Action Complaint for Violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934
U.S. District Court Civil Docket
Notice of Dismissal
—Reference Complaint Complaint Related Data is not available
Related District Court Filings
—Related District Court Filings Data is not available